The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Top Cited Papers
Open Access
- 31 May 2011
- journal article
- review article
- Published by Elsevier BV in Gastroenterology
- Vol. 140 (6), 1817-1826.e2
- https://doi.org/10.1053/j.gastro.2010.11.058
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndromeBMC Gastroenterology, 2010
- Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel diseaseInflammatory Bowel Diseases, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Metabolomics Reveals Metabolic Biomarkers of Crohn's DiseasePLOS ONE, 2009
- Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel diseaseWorld Journal of Gastroenterology, 2008
- Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndromeGut, 2007
- New serological markers in inflammatory bowel disease are associated with complicated disease behaviourGut, 2007
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitisGut, 2006
- Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal InflammationThe American Journal of Gastroenterology, 2003